๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 9 Tianjin 6 Zhengzhou 6 Xiamen 6 Guangzhou 6
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing9 Tianjin6 Zhengzhou6 Xiamen6 Guangzhou6
All 32 locations
Target enrolment
to

Trials with a site in Tianjin

6 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
NCT07585747Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
27
Shenzhen, Zhengzhou, Nanchang, Jinan, Tianjin
2026-04-15
Recruiting
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
NCT07555470Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2026-04-10
Recruiting
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
NCT07299149Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
34
Tianjin
2025-12-25
Recruiting
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
NCT06704555Follicular Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2024-12-20
Recruiting
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
NCT05846763Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Observational
50
Tianjin
2022-11-01
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
BeOne Medicines
Phase 1/2
645
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Rows per page Showing 1–6 of 6
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 6 of those studies with a site in Tianjin that also match the filters currently applied.

How many clinical trials are recruiting in Tianjin?

5 of the 6 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tianjin), 6 studies
PhaseStudiesRecruitingShare
Phase 24366.7%
Observational1116.7%
Phase 1/21116.7%

Most active sponsors

Lead sponsors with the most studies (Tianjin)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China43
BeOne Medicines11
Tianjin Medical University Cancer Institute and Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.